High concentrations of a novel peptide, neuropeptide Y, in the innervation of mouse and rat heart

Catecholaminergic and peptidergic nerve components of intramural ganglia in the rat heart. An immunohistochemical study

Immunohistochemical properties of the terminal nerve network in the rat heart were assessed by use of the elution-restaining method. The colocalization of the enzymes involved in catecholamine synthesis (tyrosine hydroxylase--TH. dopamine-beta-hydroxylase--DBH) as well as the respective distributions of the neuropeptides associated with the adrenergic nervous system (neuropeptide tyrosine--NPY, C-terminal flanking peptide of neuropeptide Y--C-PON) were studied in series of serial sections throughout the interatrial septum and the atrioventricular junction. Our data suggest that ganglion cells of sulcus terminalis as well as the epicardial ganglia enclosed between the superior vena cava and ascending aorta are VIP- and TH-negative, but neuropeptide Y- and DBH-immunoreactive. They give rise to three intraseptal nerves directed towards the specialised structures of the atrioventricular junction. These nerve fascicles contain abundant, thick TH-immunoreactive nerve fibres and scarce, thin NPY- and DBH-immunoreactive fibres. The cell bodies of the intramural ganglion cells localized between the right and left branches of the bundle of His (Moravec and Moravec 1984) are strongly TH- and DBH-immunoreactive. They are innervated by thick nerve fibres having the same immunohistochemical properties (NPY- and DBH-immunoreactivities) as those of a subpopulation of the epicardial ganglion cells and seem to supply some of the TH-immunoreactive nerve fibres directed via the intraseptal nerves to the epicardial ganglia. The existence of a multicomponent nerve network, characterized by a reciprocal innervation of the sinus node and atrioventricular node areas, is suggested by our immunohistochemical data.

N-alpha-biotinylated-neuropeptide Y analogs: syntheses, cardiovascular properties, and application to cardiac NPY receptor visualization

Two monobiotinylated analogs of neuropeptide Y (NPY) were synthesized by coupling the N-hydroxysuccinimidyl esters of biotin and (6-biotinylamido)-hexanoic acid, respectively, to the free alpha-NH2 group of the side chain protected NPY peptide resin. Crude peptides obtained by HF cleavage were purified by RPLC and their integrities were confirmed by amino acid and mass spectral analysis. As with NPY, both biotinylated analogs inhibited 125I-NPY binding and adenylate cyclase activity of rat cardiac ventricular membranes in a dose-dependent manner. N-alpha-[(6-biotinylamido)-hexanoyl]-NPY exhibited potencies comparable to that of NPY whereas N-alpha-biotinyl-NPY was slightly less potent. In the in vivo experiments, however, both the biotinylated analogs exhibited responses comparable to NPY in increasing arterial blood pressure and decreasing heart rate in anesthetized rats. The responses of the biotinyl analogs were longer lasting than those of NPY. Histochemical studies revealed that N-alpha-[(6-biotinylamido)-hexanoyl]-NPY could label the NPY receptors in rat cardiac ventricular tissues. This labeling was specific since intact NPY inhibited the staining. These studies show that biotinyl-NPY analogs exhibit biological potencies comparable to intact NPY and can therefore be used to further probe the NPY-receptor interaction.

Vagal action on atrioventricular conduction and its inhibition by sympathetic stimulation and neuropeptide Y in anaesthetised dogs

The observed change in atrioventricular conduction time (PR interval) in response to vagal stimulation is the result of two opposing effects; PR interval increases in response to the direct action of the vagus on atrioventricular nodal cells (direct effect), and the accompanying slowing of heart rate acts to decrease PR interval (indirect effect). The relationships between these opposing effects were studied in anaesthetised dogs. This study has shown that the increase in PR interval in response to vagal stimulation is well correlated with vagal stimulation frequency and can be regarded as linear. This is so for unpaced and paced hearts. We have also shown there is an increase in the sensitivity of the relationship between increase in PR interval and vagal stimulation frequency during pacing. This increase in sensitivity is attributable to the elimination of the indirect effect of the slowing of heart rate. During atrial pacing, the relationship between pulse interval and PR interval resembles a hyperbola. At low-pulse intervals (i.e. fast heart rates) the PR interval increases. This is in agreement with previous qualitative findings and is related to the functional refractory period of the atrioventricular cells. The action of sympathetic stimulation and injection of neuropeptide Y has not been studied previously. The vagally induced increase in atrioventricular conduction time is attenuated for many minutes following stimulation of the cardiac sympathetic nerve at 16 Hz for 2 min or by intravenous injection of neuropeptide Y (25-50 micrograms/kg). Stimulation of the right cardiac sympathetic nerve evokes a significantly stronger inhibition of the vagally induced prolongation of pulse interval than stimulation of the left sympathetic nerve. On the other hand, stimulation of the left or right sympathetic nerves cause similar inhibition of vagal action on atrioventricular conduction time.

Some parasympathetic neurons in the guinea-pig heart express aspects of the catecholaminergic phenotype in vivo

In a histochemical study of intrinsic cardiac ganglia of the guinea-pig in whole-mount preparations, it was found that some 70-80% of the neurons express aspects of the catecholaminergic phenotype. These neurons have an uptake mechanism for L-DOPA, and contain the enzymes for converting L-DOPA (but not D-DOPA) to dopamine and noradrenaline, i.e. aromatic L-aminoacid decarboxylase and dopamine beta-hydroxylase. Monoamine oxidase is also present within some of the neurons. In these respects, the neurons resemble noradrenergic neurons of sympathetic ganglia, so we refer to them as intrinsic cardiac amine-handling neurons. However, these neurons do not contain tyrosine hydroxylase and show little or no histochemically detectable uptake of alpha-methyldopa, dopamine or noradrenaline, even after depletion of endogenous stores of amines by pre-treatment with reserpine. Noradrenergic fibres from the sympathetic chain form pericellular baskets around nerve cell bodies. The uptake of L-DOPA into nerve cell bodies is not prevented by treatment with 6-hydroxydopamine sufficient to cause transmitter-depletion or degeneration of the extrinsic noradrenergic fibres. Such degeneration experiments suggest that axons of the amine-handling neurons project to cardiac muscle, blood vessels and other intrinsic neurons. The cardiac neurons do not show any immunohistochemically detectable serotonergic characteristics; there is no evidence for uptake of the precursors L-tryptophan and 5-hydroxytryptophan or 5-HT itself, whereas the extrinsic noradrenergic nerve fibres within the ganglia can take up 5-HT when it is applied in high concentrations.

Attenuation of long-lasting effects of sympathetic stimulation after repeated stimulation

Neuropeptide Y (NPY) is stored with norepinephrine in sympathetic nerves throughout the cardiovascular system and is released during activation of the sympathetic nervous system in humans and other animals. After stimulation of the cardiac sympathetic nerves in anesthetized dogs, the action of the vagus nerve on heart rate is attenuated for a prolonged period. This attenuation of cardiac vagal action is also seen after injection of NPY. Both sympathetic stimulation and exogenous NPY inhibit cardiac vagal effects by acting on postganglionic vagal nerves. Because the supply of neuropeptides to nerve terminals is by axonal transport, it might be expected that repeated stimulation of cardiac sympathetic nerves would deplete the sympathetic neural factor, proposed to be NPY. In all 11 dogs of this study, repeated episodes of stimulating the cardiac sympathetic nerve (16 Hz for 1 minute each) had a diminishing effect in attenuating cardiac vagal action. However, the episodes of sympathetic stimulation did not show diminishing effectiveness in increasing heart rate. Exogenous NPY had similar inhibitory effects on vagal action whether given at the beginning or the end of the episodes of sympathetic stimulation. Transmural stimulation of sympathetic nerves around rabbit ear arteries produced effects that are also mimicked by NPY. These are prolonged potentiation of contractions evoked by injection of norepinephrine or by brief bursts of transmural stimulation. Repeated stimulations in this case also had diminishing abilities to evoke such potentiations. Both sets of observations are consistent with repeated stimulation of sympathetic nerves causing depletion of a nonadrenergic transmitter, possibly NPY.

Characterization of neuropeptide Y binding sites in rat cardiac ventricular membranes

Neuropeptide Y (NPY) binding sites in rat cardiac ventricular membranes have been characterized in detail. 125I-NPY bound to the membranes with high affinity. Binding was saturable, reversible and specific, and depended on time, pH and temperature. Analysis of the binding data obtained under optimal conditions, 2 hr, 18 degrees C and at pH 7.5, revealed the presence of low and high affinity binding sites. The high affinity binding sites had an apparent dissociation constant (Kd) of 0.38 nM and a binding capacity (Bmax) of 7.13 fmol/mg protein. The apparent Kd and Bmax for low affinity binding sites were 22.34 nM and 261.25 fmol/mg protein, respectively. Peptides unrelated to NPY did not compete with 125I-NPY for the binding sites even at 1 microM concentrations, whereas homologous peptides, peptide YY (PYY) and pancreatic polypeptide (PP), and NPY(13-36) inhibited 125I-NPY binding but with lower potency compared to NPY. 125I-NPY binding was sensitive to the nonhydrolyzable GTP analog, Gpp(NH)p, suggesting that the NPY receptor is coupled to the adenylate cyclase system. The ventricular membrane receptor characterized in this study may play an important role in mediating the physiological effects of NPY in the heart.

Immunohistochemical demonstration of human cardiac innervation before and after transplantation

Knowledge about the distribution and origins of peptide-containing nerves in the innervated and transplanted heart is lacking. Immunohistochemical and histochemical techniques were used to visualize human cardiac innervation before and after transplantation. In the recipient heart cardiac nerve fibers and fascicles displayed immunoreactivity for general neural (protein gene product 9.5 and synaptophysin) and Schwann cell markers (S-100). A major proportion of cardiac nerves displayed neuropeptide tyrosine and tyrosine hydroxylase immunofluorescence staining. Subpopulations of nerves contained somatostatin, vasoactive intestinal polypeptide, calcitonin gene-related peptide, substance P- or neurokinin-like immunoreactivity, and acetylcholinesterase activity. Tissues from cardiac allografts (5 weeks to 63 months after transplantation) contained nerves and ganglion cells that were acetylcholinesterase positive and immunoreactive for the general neural markers. These nerves were less numerous than in recipient hearts and rarely displayed neuropeptide immunostaining. Atrial natriuretic peptide immunoreactivity was localized to myocardial cells in transplanted hearts as well as explanted recipient and postmortem hearts. While most human cardiac allografts remain functionally extrinsically denervated, they appear to contain viable intrinsic nerves, and myocardial cells retain the capacity to produce atrial natriuretic peptide.

Interaction of 125I-neuropeptide Y with rat cardiac membranes

125I-Neuropeptide Y (NPY) bound specifically with high affinity to rat atrial and ventricular membranes. Scatchard analysis revealed the presence of single class of binding sites in both atrial and ventricular membranes. The apparent Kd and Bmax for atrial membranes were 0.63 nM and 70 fmol/mg protein, respectively; ventricular membranes had an apparent kd of 0.39 nM and a Bmax of 283 fmol/mg protein. NPY structural homologues peptide YY (PYY) and pancreatic polypeptide (PP) bound to the ventricular membranes NPY receptor, but with several fold lower potency compared to NPY. Binding of 125I-NPY to ventricular membranes was sensitive to guanosine triphosphate (GTP) suggesting that the NPY receptor is linked to adenylate cyclase system. The receptor characterized in this system may play a crucial role in mediating the cardiac effects of NPY.

Neuropeptide Y (NPY)-containing nerves in mammalian ureter

The distribution of neuropeptide Y in the ureter of the rat, rabbit, and man has been determined by radioimmunoassay and chromatographic analysis of the tissue extract. The localization of neuropeptide Y-immunoreactivity has been identified by immunocytochemistry. A regional distribution of neuropeptide Y was found; highest concentrations being present in the ureterovesical junction. Throughout the ureter, neuropeptide Y-immunoreactive nerve fibers were identified to surround the blood vessels and a few plexuses of neuropeptide Y-containing nerves were present within the muscle layers. Neuropeptide Y was not present within ganglion cells. Treatment of rats with 6-hydroxydopamine resulted in a significant reduction of neuropeptide Y concentrations in the upper, middle, and lower thirds of the ureter. This depletion in extractable neuropeptide Y was associated with morphologic changes typical of axonal degeneration of the neuropeptide Y-containing nerve fibers.

Target influences on transmitter choice by sympathetic neurons developing in the anterior chamber of the eye

In contrast to the majority of sympathetic neurons which are noradrenergic, the sympathetic neurons which innervate sweat glands are cholinergic. Previous studies have demonstrated that during development the sweat gland innervation initially contains catecholamines which are lost as cholinergic function appears. The neurotransmitter phenotype of sweat gland neurons further differs from the majority in that they contain vasoactive intestinal peptide (VIP) rather than neuropeptide Y (NPY). In the experiments described here, we addressed the question of whether sympathetic targets influence the neurotransmitter-related properties of the neurons which innervate them; in particular, do sweat glands play a role in reducing the expression of noradrenergic properties and inducing the expression of cholinergic properties and VIP in sympathetic neurons? This was accomplished by cotransplanting to the anterior chamber of the eye of host rats the superior cervical ganglia (SCG) which contains neurons that normally innervate targets other than the sweat glands and differentiate noradrenergically and footpad tissue from neonatal rats. Sweat glands developed in the transplanted footpad tissue and became innervated by the cotransplanted SCG neurons. The transplanted neurons and sweat gland innervation initially exhibited catecholamine histofluorescence which declined with further development in the anterior chamber. After 4 weeks, choline acetyltransferase (ChAT) and VIP immunoreactivities were evident. These observations suggest that as in the neurons which innervate the glands in situ, noradrenergic properties were suppressed and cholinergic function was induced in the neurons which innervated the glands in oculo. To distinguish a specific influence of the sweat glands on transmitter choice, SCG were also cotransplanted with the pineal gland, a normal target of the ganglion. Neurons cotransplanted with the pineal gland continued to exhibit catecholamine histofluorescence and contained NPY immunoreactivity. At least some neurons in SCG/pineal cotransplants, however, developed ChAT immunoreactivity. The target-appropriate expression of catecholamines and peptides in these experiments is consistent with the hypothesis that some transmitter properties are influenced by target tissues. The indiscriminant expression of ChAT, however, suggests that at least in oculo, additional factors can influence transmitter choice.

Inhibition of noradrenaline release by neuropeptide Y in mouse atria does not involve inhibition of adenylate cyclase or a pertussis toxin-susceptible G protein

Neuropeptide Y (30-1000 nmol/l) significantly inhibited the fractional stimulation-induced outflow of radioactivity from mouse atria preincubated with [3H]-noradrenaline. The inhibitory effect of neuropeptide Y was observed at all frequencies tested (2, 5 and 10 Hz) as well as after alpha-adrenoceptor blockade with phentolamine (1 mumol/l). A combination of 8-bromo adenosine cyclic-3'-5'-monophosphate (90 or 270 mumol/l) with the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine (100 mumol/l) was used to saturate maximally the adenylate cyclase system and these drug combinations significantly enhanced the stimulation-induced outflow of radioactivity. However, neuropeptide Y inhibited the stimulation-induced outflow in the presence of these drugs, suggesting that the inhibitory effect of neuropeptide Y was not due to decreasing endogenous cyclic AMP formation. Finally, atria from mice treated with pertussis toxin were used. In this case, the inhibitory effect of neuropeptide Y on the stimulation-induced outflow of radioactivity was still observed suggesting that inhibitory prejunctional neuropeptide Y receptors are not coupled to a pertussis toxin-susceptible G protein.

Adrenergic neurons and short proprioceptive feedback loops involved in the integration of cardiac function in the rat

Serial cryostat and paraffin-embedded sections through the atrioventricular junction of the rat heart were studied at the light-microscopic level after indirect immunohistochemical staining (tyrosine hydroxylase, neuropeptide Y, C-terminal flanking peptide of neuropeptide Y immunoreactivities) or silver impregnation. The distribution of these immunoreactivities in the Hissian ganglion (Moravec and Moravec 1984) as well as the relationships of the Hissian ganglion cells with the surrounding structures have been studied to assess its function. The results suggest that the Hissian ganglion is composed of large multipolar neurons displaying both tyrosine hydroxylase (TH) and related peptide (neuropeptide Y. C-terminal flanking peptide of neuropeptide Y) immunoreactivities. The dendritic projections of these adrenergic cells penetrate the reticular portion of the atrioventricular node and the upper segments of the interventricular septum where they constitute sensory-like corpuscles. The hypothesis that the adrenergic neurons of the atrioventricular junction are involved in short proprioceptive feedback loops necessary for beat-to-beat modulation of cardiac excitability and intracardiac conduction can thus be suggested.

Changes in cardiac neuropeptide Y after experimental myocardial infarction in rat

We have investigated the hypothesis that neuropeptide Y (NPY) is released from noradrenergic sympathetic nerves during experimentally induced myocardial infarction. A left thoracotomy was performed, the left main coronary artery ligated, and the animals sacrificed 4 or 48 h later. NPY levels in heart tissue from these rats and sham-operated controls were measured with radioimmunoassay. Levels of NPY in the right atrium were greater than other regions of the rat heart. After ligation of the left coronary artery, the concentration of NPY in the infarcted area of the left ventricle was reduced at 4 and 48 h when compared to a similar area in sham-operated rats. NPY levels in the septum were unchanged. The results suggest that during myocardial infarction, NPY is released from nerves in the infarcted region and may deleteriously affect increased collateral blood flow surrounding the infarcted tissue.

The negative inotropic effect of neuropeptide Y on the ventricular cardiomyocyte

The effect of neuropeptide Y (NPY) on cell contractions of ventricular myocytes isolated from the adult rat heart was investigated. Maximum changes in cell length (dL) during stimulated (0.5 Hz) contractions were determined in presence of the phosphodiesterase inhibitor Ro 20-1724 (0.5 mM) and adenosine deaminase (5 U/ml). Under these basal conditions NPY (10(-6) M) reduced dL by 39% of control. Isoproterenol (10(-6) M) increased dL by 105% of control; the EC50 was 2 x 10(-9) M. NPY reduced the increase in dL achieved by isoproterenol in a dose dependent manner. The IC50 value was 1 x 10(-9) M and NPY (10(-6) M) produced complete inhibition. In the absence of the phosphodiesterase inhibitor the IC50 was 4 x 10(-9) M. The EC50 of isoproterenol and IC50 of NPY producing accumulation of cAMP in myocytes (Millar et al. 1988) exceeded the respective values of dL by one order of magnitude. Prior treatment of the myocytes with pertussis toxin abolished the potency of NPY to antagonize the increase in dL by isoproterenol while not interfering with the response to the beta-agonist. These results demonstrate a negative inotropic effect of NPY on the ventricular myocardial cell. Complete abolition of the effect of NPY by pertussis toxin indicate that this effect is mediated by a sarcolemmal receptor for NPY linked to adenylate cyclase via an inhibitory guanine nucleotide binding protein.

Distribution and density of neuropeptide Y-immunoreactive nerve fibres and cells in the horse urinary bladder

The distribution and density of neuropeptide Y (NPY)-immunoreactive nerve fibres and cells were determined in the urinary bladder of the horse by using the peroxidase-antiperoxidase (PAP) immunohistochemical method. Numerous undulating NPY-immunoreactive nerve fibres were found throughout the vesical wall, sometimes forming nerve bundles which ramified repeatedly as they coursed through the connective tissue septa to give rise to smaller bundles or single fibres which projected into the muscle fascicles forming muscular nerve plexuses, mainly in the bladder base. In the submucosa of this region, NPY-immunoreactive fibres formed a rather dense subepithelial plexus. Numerous NPY-immunoreactive nerve fibres supplied blood vessels and were widely distributed on the vascular adventitia constituting rich perivascular nerve plexuses. In addition, intramural ganglia containing NPY-immunoreactive nerve cell bodies and fibres were identified at the uretero-vesical junction. These results suggest that the equine urinary bladder possesses a rich NPY-peptidergic innervation which shows regional variations in the density of the muscular and subepithelial plexuses, the bladder base being the most richly innervated region. At least some of these NPY-immunoreactive nerve fibres have an intrinsic origin in ganglion cells within the vesical wall.

Localization of adrenergic and neuropeptide tyrosine-containing nerves in the mammalian liver

The distribution of adrenergic nerves in guinea pig and rat liver was studied by the immunolocalization of fibers containing tyrosine hydroxylase and dopamine beta-hydroxylase, enzymes involved in the synthesis of catecholamines. In both species, adrenergic fibers were identified within portal tracts, often in close proximity to hepatic artery branches. In guinea pig liver, but not rat liver, abundant intraacinar fibers were identified; fibers were also seen within the walls of terminal hepatic vein radicles and larger hepatic veins. The presence of peptidergic nerves containing the regulatory peptide neuropeptide tyrosine and the C-flanking peptide CPON was investigated by indirect immunofluorescence. The distribution of these nerves was similar to that of tyrosine hydroxylase- and dopamine beta-hydroxylase-positive nerves and showed the same species difference. The effector sympathetic nature of tyrosine hydroxylase- and neuropeptide tyrosine-positive fibers in rat liver was confirmed by chemical denervation studies using 6-hydroxydopamine.

Neuropeptide Y as a putative modulator of the vagal effects on heart rate

Neuropeptide Y is stored in sympathetic nerve terminals throughout the heart and has direct and indirect effects on cardiac function. Although neuropeptide Y has been shown to be released upon intense (16-30 Hz) cardiac sympathetic stimulation, we sought to determine whether effective quantities of neuropeptide Y were released from cardiac sympathetic neurons under more natural conditions. We recorded arterial pressure and cardiac cycle length in 29 anesthetized dogs. We assessed neuropeptide Y release by measuring the attenuation of vagally induced increases in cardiac cycle length (10 seconds every 2 minutes) after trains of sympathetic stimulation. We examined the effect of constant-frequency sympathetic stimulation (frequencies of 2, 5, 10, and 15 Hz, applied for train durations of 1, 3, and 5 minutes) on vagally induced chronotropic responses. We also determined the effect of varying the pattern of sympathetic stimulation. Both the magnitude and duration of the inhibition of the vagal effects on cardiac cycle length were augmented significantly by increases in the frequency or duration of sympathetic stimulation. In contrast, the inhibition of the vagally induced chronotropic responses was not significantly affected by changes in the pattern of sympathetic stimulation. We also characterized the role of adrenergic receptors. Phentolamine significantly increased the sympathetically mediated inhibition of the vagal effects on cardiac cycle length, but propranolol had no effect.(ABSTRACT TRUNCATED AT 250 WORDS)

Heart innervation after ligation of the left anterior descending coronary artery (LAD)

Distribution and amount of neuropeptide Y- and synaptophysin-immunoreactive nervous structures within the heart were investigated in dogs 4 days after ligation of the left anterior descending coronary artery (LAD). In the right atrium and posterior left ventricular regions, which were taken as (non-infarcted) control areas, neuropeptide Y-immunoreactive paravascular nerves and a perivascular nerve plexus running within the adventitia of the coronary arteries and their branches down to the arterioles were observed. Morphometric measurements of the area density revealed 0.099 +/- 0.014% for synaptophysin- and 0.037 +/- 0.0072% for neuropeptide Y-immunoreactivity within the posterior wall of the left ventricular myocardium. Four days after ligation of the LAD only single synaptophysin- and neuropeptide Y-immunoreactive nerve fibers were very rarely detected in the infarcted region of the anterior wall of the left ventricle. Above the ligature larger than normal neuropeptide Y-immunoreactive axons within nerves along the LAD indicated a blockage of the axoplasmic transport of this peptide. When investigating this model of experimental myocardial infarction, mechanical traumatization of peri- and paravascular nerves of the LAD by the ligature has to be considered as a major pathogenetic factor, in addition to ischemia leading to denervation of infarcted as well as non-ischemic myocardium.

Characterization and presynaptic modulation of stimulation-evoked exocytotic co-release of noradrenaline and neuropeptide Y in guinea pig heart

The relationship between noradrenaline and neuropeptide Y (NPY) release was investigated in the in situ perfused guinea pig heart with intact sympathetic innervation. For determination of NPY concentrations in the perfusate, a specific radioimmunoassay was employed and further characterized. Electrical stimulation of the left stellate ganglion (4, 8, 12, and 50 Hz; for 10 min) evoked a calcium-dependent and frequency-related overflow of noradrenaline and NPY, which was positively correlated (r = 0.83; p less than 0.001; n = 25). When two subsequent stimulations (12 Hz; each for 1 min) were performed in the same heart, addition of noradrenaline (10 microM) 5 min prior to the second stimulation reduced NPY overflow by 43 +/- 10%. The stimulated release of noradrenaline and NPY was increased by the alpha 2-adrenoceptor antagonist yohimbine (1 microM) to 170 +/- 10% and 199 +/- 26%, and attenuated by the alpha 2-adrenoceptor agonist B-HT 920 (1 microM) to 70 +/- 9% and 68 +/- 9%, respectively. The adenosine analogue cyclohexyladenosine (1 microM) significantly reduced the stimulated overflow of both noradrenaline (to 57 +/- 5%) and NPY (to 73 +/- 8%). Exogenous NPY (100 nM) attenuated the stimulated overflow of noradrenaline by 30 +/- 6%. Uptake1 blockade with desipramine (100 nM) or nisoxetine (100 nM) prior to the second stimulation significantly increased noradrenaline overflow and attenuated that of NPY; the attenuation of the stimulation-evoked overflow of NPY was abolished by yohimbine (1 microM). Our results indicate that electrical stimulation induces a calcium-dependent, exocytotic co-release of noradrenaline and NPY.(ABSTRACT TRUNCATED AT 250 WORDS)

Dependence of non-adrenergic inhibition of cardiac vagal action on peak frequency of sympathetic stimulation in the dog

1. It is known that stimulation of the sympathetic cardioaccelerator nerve is followed by prolonged inhibition of cardiac vagal action. This prolonged inhibitory action of the sympathetic nerve is not blocked by alpha- or beta-adrenoceptor blockade, and is not duplicated by administration of noradrenaline. It has been proposed that it is due to the release of neuropeptide Y (NPY) from the sympathetic nerve terminals (Potter, 1984, 1985). 2. The present experiments examined whether prolonged inhibition of cardiac vagal action could be preferentially produced by sympathetic stimulation of different temporal distribution. The experiments were performed on anaesthetized, vagotomized dogs, with pharmacological beta-adrenoceptor blockade. 3. In six animals intermittent supramaximal sympathetic stimulation at 20 Hz (1/2 s stimulation, 1/2 s off; train duration 2 min; total 1200 stimuli) produced significantly greater inhibition (P less than 0.01) of cardiac vagal action than did continuous stimulation at 5 Hz (stimulus duration 4 min; 1200 stimuli). 4. In another series the same total period of stimulation (2.5 min; 1200 stimuli) was used and it was found that intermittent sympathetic stimulation of 16 Hz (1/2 s stimulation, 1/2 s off) produced significantly greater cardiac vagal inhibition (P less than 0.02) than continuous stimulation at 8 Hz. In this case the mean frequency of stimulation was constant but the higher peak stimulation frequency attenuated cardiac vagal action more effectively.

Immunohistochemical and ultrastructural localisation of peptide-containing nerves and myocardial cells in the human atrial appendage

The innervation and myocardial cells of the human atrial appendage were investigated by means of immunocytochemical and ultrastructural techniques using both tissue sections and whole mount preparations. A dense innervation of the myocardium, blood vessels and endocardium was revealed with antisera to general neuronal (protein gene product 9.5 and synaptophysin) and Schwann cell markers (S-100). The majority of nerve fibres possessed neuropeptide Y immunoreactivity and were found associated with myocardial cells, around small arteries and arterioles at the adventitial-medial border and forming a plexus in the endocardium. Subpopulations of nerve fibres displayed immunoreactivity for vasoactive intestinal polypeptide, somatostatin, substance P and calcitonin gene-related peptide. In whole-mount preparations of endocardium, substance P and calcitonin gene-related peptide immunoreactivities were found to coexist in the same varicose nerve terminals. Ultrastructural studies revealed the presence of numerous varicose terminals associated with myocardial, vascular smooth muscle and endothelial cells. Neuropeptide Y immunoreactivity was localised to large electron-dense secretory vesicles in nerve terminals which also contained numerous small vesicles. Atrial natriuretic peptide immunoreactivity occurred exclusively in myocardial cells where it was localised to large secretory vesicles. The human atrial appendage comprises a neuroendocrine complex of peptide-containing nerves and myocardial cells producing ANP.

Neuropeptide Y-containing neurons in the rat striatum: ultrastructure and cellular relations with tyrosine hydroxylase- containing terminals and with astrocytes

The ultrastructural localization of neuropeptide Y (NPY) was comparatively examined in the dorsal (caudate-putamen) and ventral (nucleus accumbens) striatum using the peroxidase-antiperoxidase (PAP) method. In both striatal regions, NPY-like immunoreactivity (IR) was detected in perikarya, dendrites and axons. The labeled perikarya were 15-25 microns in a diameter and contained large, deeply and multiply indented nuclei and prominent Nissl bodies. The labeled dendrites contained a few large (80-150 nm) dense-core vesicles, lacked detectable spines and received few afferents. These morphological characteristics of NPY-IR neurons in both areas are in close accord with previous descriptions for the medium aspiny intrinsic neurons. Axon terminals with terminals with NPY-like IR contain primarily small clear round vesicles, as seen in single or serial sections. These terminals formed junctions that lacked recognizable pre- or post- synaptic densities, but showed parallel spacing between apposed plasmalemmas at presumed synaptic clefts. Targets of the axon terminals with NPY-like IR included unlabeled somata, unlabeled proximal dendrites and labeled and unlabeled distal dendrites. The NPY-IR neurons in the caudate-putamen differed from those in the nucleus accumbens in that (1) there were no recognized appositions between labeled dendrites and labeled terminals, and (2) fewer terminals contained large dense-core vesicles. These findings are consistent with the concept that in the nucleus accumbens, the excitability of the NPY-IR neurons may be more directly modulated by NPY or another transmitter co-existing in the terminals. Catecholamines are known to co-exist with NPY in certain rostrally projecting brainstem nuclei. Therefore, in the two striatal regions, we additionally sought to determine (1) whether the NPY-IR neurons might be modulated by catecholaminergic afferents and (2) whether NPY might co-exist with catecholamines in terminals. Goat antiserum against NPY and rabbit antiserum against tyrosine hydroxylase (TH), the catecholamine-synthesizing enzyme, were simultaneously localized in single sections by PAP and immunoautoradiographic methods, respectively. Quantitative analysis in dually labeled sections from both striatal areas revealed few, if any, direct synaptic contacts between TH-labeled terminals and dendrites containing NPY-like IR. However, there was convergence of separate NPY- and TH-IR terminals on unlabeled dendrites. A few terminals in the nucleus accumbens, but not in the dorsal striatum, showed immunoreactivity methods, to TH and also contained dense-core vesicles with NPY-like IR.(ABSTRACT TRUNCATED AT 400 WORDS)

Renal sympathetic nerve activation in relation to reserpine-induced depletion of neuropeptide Y in the kidney of the rat

The effect of reserpine treatment on renal sympathetic nerve activity and tissue levels of neuropeptide Y (NPY)-like immunoreactivity (LI) and noradrenaline (NA) were studied in rats. Injection of reserpine (1 mg kg-1 i.v.) caused a clear-cut (about 50%) increase in rectified activity of the post-ganglionic sympathetic nerves to the kidney within 15 min in chloralose-anaesthetized rats compared to a saline-treated control group. This increase in nerve activity was still maintained 120 min after the reserpine injection. The renal nerve activation was accompanied by a progressive fall in mean arterial blood pressure and an initial tachycardia. In a separate group of conscious rats, the levels of NPY-LI (1.3 +/- 0.06 pmol g-1) and NA (1.6 +/- 0.07 nmol g-1) in the kidney were significantly reduced (by 74 and 83%, respectively) 24 h after reserpine treatment (1 mg kg-1 i.v.). The reserpine-induced depletion of NPY-LI, but not that of NA, was inhibited by pretreatment with the ganglionic blocking agent chlorisondamine or the alpha 2-adrenoceptor agonist clonidine, both of which are known to decrease renal sympathetic nerve activity. The tissue content of NPY-LI in the right atrium (16.3 +/- 0.7 pmol g-1) was not reduced by reserpine. Arterial plasma NPY-LI in the rat was high (222 +/- 5 pmol l-1), and this value did not change after pretreatment with reserpine, chlorisondamine or clonidine, indicating that, in the rat, circulating NPY-LI is not a good indicator of sympatho-adrenal activity.(ABSTRACT TRUNCATED AT 250 WORDS)

Pre- and postjunctional effects of neuropeptide Y on the rabbit isolated ear artery

1. In the isolated perfused and superfused rabbit ear artery, neuropeptide Y (NPY, 0.3-100 nmol/l) had no direct vasoconstrictor action, but produced a concentration-dependent and reversible enhancement of vasoconstrictor responses to both sympathetic nerve stimulation and exogenous noradrenaline. 2. In arteries in which the noradrenergic transmitter stores had been radiolabelled with [3H]-noradrenaline, 100 nmol/l NPY inhibited the stimulation-induced (1 Hz for 30 s) release of radioactivity, but the lower concentrations tested (10 and 30 nmol/l) had no effect. NPY (10, 30 and 100 nmol/l) had no effect on the resting release of radioactivity. 3. Thus, NPY in low concentrations enhances vasoconstrictor responses in the rabbit ear artery by a postjunctional action; prejunctionally, NPY inhibits stimulation-induced transmitter release when it is present in high concentrations.

Pterygopalatine ganglion cells contain neuropeptide Y

By immunohistochemistry, neuropeptide Y (NPY) localizes to neurons in the rat pterygopalatine ganglion. These cells also are intensely or moderately reactive with acetylcholinesterase histochemistry. In contrast, both tyrosine hydroxylase immunohistochemistry and glyoxylic acid-induced fluorescence for catecholamines stain smaller clustered cells, similar in appearance to small intensely fluorescent (SIF) cells and clearly distinct from the NPY-immunoreactive cells. By reverse phase high-performance liquid chromatography, the NPY-immunoreactive material in the rat pterygopalatine ganglion migrates as a single peak characteristic of the peptide. We conclude that NPY-containing cholinergic cells are present in this classical parasympathetic ganglion. NPY-like immunoreactive neurons similarly occur in the pterygopalatine ganglion of the guinea pig.

Differential effects of surgical sympathectomy on rat heart concentrations of neuropeptide Y-immunoreactivity and noradrenaline

The aim of this study was to estimate the proportion of cardiac neuropeptide Y-immunoreactivity (NPY-ir) which is not present in sympathetic neurones innervating the rat heart. The procedure employed was to surgically sympathectomize the heart and then measure the remaining cardiac concentrations of NPY-ir and noradrenaline (NA). Unilateral (left) sympathectomy significantly reduced the levels of NPY-ir and NA in all regions of the heart (by 40-70%) except for the NPY-ir in the right atrium which was unaltered. The effect of bilateral sympathectomy was significantly greater than that of unilateral sympathectomy. Unilateral and bilateral sympathectomy produced similar reductions in the concentrations of NPY-ir and NA in the ventricular tissue. In contrast dissimilar changes were produced in the atrium. Although bilateral sympathectomy almost totally depleted the NA from the right atrium (by 98%), the NPY-ir levels were only reduced by 50%. These results indicate that approximately half the content of NPY in the right atrium is not present in sympathetic noradrenergic neurones. This pool may occur in the previously described intrinsic neurones of the right atrium.

Guanethidine blocks neuropeptide-Y-like inhibitory action of sympathetic nerves on cardiac vagus

In the anaesthetised dog there is prolonged attenuation of cardiac vagal action following electrical stimulation of the cardiac sympathetic nerve or intravenous injection of neuropeptide Y (NPY). The effect survives alpha- and beta-adrenoceptor blockade, and is not mimicked by exogenous noradrenaline. Guanethidine blocks the attenuation of cardiac vagal action following sympathetic stimulation but not after injection of NPY. It is suggested that NPY is released from cardiac sympathetic neurons with noradrenaline following activation of the sympathetic nerve and inhibits cardiac vagal action.

Immunocytochemical localisation of neuropeptide Y and 5-hydroxytryptamine in a subpopulation of amine-handling intracardiac neurones that do not contain dopamine beta-hydroxylase in tissue culture

The colocalisation of neuropeptide Y (NPY)- and 5-hydroxytryptamine (5-HT)-immunoreactivities in intracardiac neurones in dissociated cultures from the atria and interatrial septum of newborn guinea pig heart was demonstrated by the sequential application of specific antisera which were visualised by two different fluorochromes. In this way it was observed that most 5-HT-immunoreactive neurones also contained NPY-immunoreactivity (approximately 40% of identified neurones), some neurones were 5-HT-immunoreactive alone (approximately 10%), while neurones that were NPY-immunoreactive only were rarely seen. No dopamine beta-hydroxilase (DBH)-immunoreactive intracardiac neurones were demonstrated in any of the culture preparations studied, although DBH-immunoreactive neurons could be detected in sections of the newborn guinea pig heart containing intracardiac ganglia. The possible implications of the colocalisation of 5-HT, that has been taken up from the culture medium, with NPY in a population of intracardiac neurones are discussed; and reasons for the loss of expression of DBH by these neurones under the conditions of culture are considered.

Evidence for uptake and synthesis of 5-hydroxytryptamine by a subpopulation of intrinsic neurons in the guinea-pig heart

Using an indirect immunofluorescence technique, a subpopulation of 5-hydroxytryptamine-like immunoreactive neurons was observed in cell cultures dissociated from the atria and interatrial septum of newborn guinea-pig heart maintained in fetal calf serum-supplemented medium. 5-Hydroxytryptamine has not been demonstrated in intracardiac neurons in situ, and since 5-hydroxytryptamine has been previously shown to be a constituent of fetal calf serum, the 5-hydroxytryptamine-like immunoreactivity seen in culture may have been the result of neuronal uptake of 5-hydroxytryptamine from the growth medium. This was examined by growing the cultures in a serum-free, hormone-supplemented, defined medium. Under these conditions, 5-hydroxytryptamine-like immunoreactive neurons were not present. When cultures were grown in hormone-supplemented, defined medium containing 10(-4) to 10(-6) M 5-hydroxytryptamine, some intracardiac neurons accumulated 5-hydroxytryptamine. This type of neuron also developed 5-hydroxytryptamine-like immunoreactivity after incubation with 5 X 10(-5) M 5-hydroxytryptophan, indicating that the subpopulation of intracardiac neurons which can take up exogenous 5-hydroxytryptamine can also synthesize it from 5-hydroxytryptophan. However, no 5-hydroxytryptamine-like immunoreactive neurons were observed after incubation with L-tryptophan, the other 5-hydroxytryptamine precursor molecule. Under all of the conditions described, some small, 5-hydroxytryptamine-like immunofluorescent cells, very similar to the catecholamine-containing, small intensely fluorescent cells of the heart, were observed in culture. Bright, 5-hydroxytryptamine-like immunoreactive endothelial cells were seen only in cultures maintained in defined medium and loaded with 5-hydroxytryptamine. The present study shows that some intracardiac neurons are amine-handling, and also raises the possibility that 5-hydroxytryptamine is utilized as a neurotransmitter or neuromodulator by these neurons in the mammalian heart. Further, there is evidence to suggest that two populations of small intensely fluorescent cells, one containing 5-hydroxytryptamine, the other a catecholamine, are present in the heart; and to indicate that atrial endothelial cells can take up 5-hydroxytryptamine.

Peptides in the mammalian cardiovascular system

Ample immunocytochemical evidence is now available demonstrating that several peptides are present in the mammalian cardiovascular system where they are localised to nerve fibres and myocardial cells. The neuropeptides (neuropeptide Y, calcitonin gene-related peptide, tachykinins and vasoactive intestinal polypeptide) are localised to large secretory vesicles in subpopulations of afferent or efferent nerves supplying the heart and vasculature of several mammals, including man. Although they often exert potent pharmacological effects on the tissues in which they occur their physiological significance has still to be established. They may act directly via specific receptors and/or indirectly by influencing the release and action of other cardiovascular transmitters. In marked contrast, atrial natriuretic peptide is produced by cardiac myocytes and considered to act as a circulating hormone.

Structure and expression of the rat neuropeptide Y gene

Neuropeptide Y is a 36-amino acid peptide that is abundant throughout the mammalian nervous system. It belongs to the same family of carboxyl-terminally amidated peptides as pancreatic polypeptide and peptide YY. We describe here the gene encoding the rat neuropeptide Y precursor. The gene spans 7.2 kilobase pairs and contains four exons. The exon organization is identical to the pancreatic polypeptide gene, although the amino acid sequences of the neuropeptide Y and pancreatic polypeptide precursors differ extensively. The predicted amino acid sequence of mature rat neuropeptide Y is identical to the human sequence. Also the sequence of the 30-amino acid carboxyl-terminal peptide of preproneuropeptide Y is highly conserved, which suggests that it is functionally important. Two neuropeptide Y alleles were found to differ at nine positions in 2.5 kilobase pairs at the 5' portion of the gene. No exon difference was found. One nucleotide substitution close to the gene promoter may influence the regulation of expression. Neuropeptide Y mRNA was found in all rat brain subregions tested, which shows that neuropeptide Y is synthesized throughout the brain. Developmentally, mRNA was detected in the rat brain as early as embryonic day 16 and increased rapidly to adult levels. The level of neuropeptide Y mRNA was also studied in several rat peripheral organs. Unexpectedly high levels were observed in heart and spleen. This mRNA may be synthesized in intrinsic ganglia and non-neuronal cells, respectively.

Excitation of carotid body chemoreceptors by neuropeptide-Y

Neuropeptide-Y (NPY) is a peptide co-localised with noradrenaline in many sympathetic nerves. Recently, it has been found in postganglionic sympathetic nerves running to blood vessels in the carotid body. When NPY is administered to cats by infusion into the arterial blood close to the carotid bodies, breathing is stimulated. This effect is abolished when the carotid sinus nerves are cut. Similar intra-carotid infusions of NPY can be demonstrated to increase the frequency of firing of chemoreceptor afferent nerves. However, NPY introduced into the blood vessels of the carotid body immediately prior to halting its blood flow does not modify the development of chemoreceptor discharge in response to developing asphyxia. The findings are consistent with NPY causing excitation of chemoreceptors by causing local vasoconstriction and stagnant asphyxia.

Presynaptic action of neuropeptide Y in area CA1 of the rat hippocampal slice

1. Neuropeptide tyrosine (neuropeptide Y, NPY), a recently isolated endogenous brain peptide, reduces the extracellular population spike evoked by stimulation of stratum radiatum in area CA1 of the in vitro rat hippocampal slice, without reducing the antidromically evoked population spike. To test the hypothesis that NPY acts presynaptically, intracellular recordings were made of pyramidal neurones of area CA1 in vitro. 2. Bath application of 10(-6) M-NPY causes a long-lasting (1-1.5 h), reversible reduction of the orthodromically evoked excitatory post-synaptic potential (e.p.s.p.) recorded intracellularly from CA1 pyramidal neurones. This effect on the e.p.s.p. was dependent upon the concentration of NPY. 3. The resting membrane potential, slope input resistance, and action potential threshold, amplitude and duration of the CA1 pyramidal neurones were not affected by NPY. 4. The responses of CA1 pyramidal neurones to ionophoretic pulses of glutamate, applied to the dendrites during synaptic blockade, was also unaffected by NPY. 5. The evidence supports the hypothesis that NPY acts presynaptically in the CA1 region of hippocampus to reduce excitatory input to the pyramidal neurones.

Light and electron microscopic demonstration of neuropeptide Y-like immunoreactive nerves in human cardiac muscle

Neuropeptide Y (NPY)-like immunoreactive nerves were demonstrated in human cardiac muscle. The atrial specimens were obtained from open-heart surgery. The PAP method was applied for immunocytochemistry for light and electron microscopy. A dense, extensive network of NPY-like immunoreactive nerve fibres was seen between cardiac muscle cells and around blood vessels. In electron microscope PAP precipitates were localized in large dense-cored vesicles of 80-120 nm in size in separate nerve terminals or in the terminals situated in the nerve bundles. Close contacts were observed between NPY nerves and muscle cells and blood vessels. The possible functional role of NPY innervation in the human heart is discussed.

Significant depletion of NPY in the innervation of the rat mesenteric, renal arteries and kidneys in experimentally (aorta coarctation) induced hypertension

The distribution and concentrations of neuropeptide Y (NPY) in kidneys, renal arteries, heart, aorta, mesenteric artery and adrenal glands from aorta-ligated hypertensive rats were studied by immunocytochemistry and radioimmunoassay. Immunocytochemistry showed that in the hypertensive animals NPY-immunoreactive fibres were decreased in both kidney and renal artery, above and below the ligation, and in mesenteric arteries. The depletion of NPY-containing nerves in the kidney was more pronounced around the juxtaglomerular apparatus than in other areas of the organ. By radioimmunoassay, the concentrations of NPY immunoreactivity were significantly lower in the hypertensive animals when compared with the controls, (kidney: hypertensive 1.0 +/- 0.1; controls 2.0 +/- 0.2 pmol/g, mean +/- SEM; p less than 0.05 renal artery: hypertensive 5.0 +/- 0.8; controls 12.1 +/- 2.0; p less than 0.05 and mesenteric artery: hypertensive 8.6 +/- 1.9; 17.6 +/- 3.0; p less than 0.01). While there were no statistically significant changes in the levels of NPY immunoreactivity in the other areas studied, there was a general trend for the level to fall in the renal artery below the ligation (hypertensive 10.6 +/- 1.5; control 15.3 +/- 2.4; p greater than 0.05). It is of interest that changes were observed in the vasoconstrictor peptide NPY in this commonly used model of hypertension.

The cardiovascular response to epicardial application of neurotensin in guinea pigs

Topical application of picomoles of neurotensin (NT) on the surface of the left ventricle (epicardial application) of anesthetized guinea pigs evoked dose-dependent pressor effects and tachycardia. The pressor response to epicardial NT was attenuated by pentolinium, a mixture of phentolamine and propranolol, or by guanethidine. However it was not affected by indomethacin, atropine or by a mixture of mepyramine and cimetidine. The tachycardia caused by epicardial NT was not modified by any of the aforementioned drugs. Both the pressor effects and tachycardia elicited by epicardial application of NT were markedly inhibited by chronic treatment of guinea pigs with capsaicin, and by topical application of lidocaine or tetrodotoxin to the surface of the left ventricle. Epicardial application of calcitonin gene-related peptide (CGRP), substance P (SP) or capsaicin also elicited tachycardia and either a decrease (CGRP and SP) or increase of blood pressure (capsaicin) in anesthetized guinea pigs. Epicardial application of NT, CGRP, or capsaicin in isolated, perfused hearts of guinea pigs also caused tachycardia. Together, these results suggest that the pressor responses to topical application of NT on the surface of the left ventricle in anesthetized guinea pigs are partially reflex in nature and likely to result from the stimulation by NT of cardiac sympathetic, capsaicin-sensitive, sensory nerve endings, whereas the tachycardia caused by epicardial NT appears to be due both to direct and indirect effects of NT on ventricular muscle cells. The possible participation of CGRP and/or SP in the chronotropic effect of NT applied on the epicardium, and their putative role as neurotransmitter of cardiac, capsaicin-sensitive, sensory neurons are discussed.

Demonstration of a neuropeptide Y (NPY)-like immunoreactivity in the pigeon retina

The distribution of neuropeptide Y (NPY)-like immunoreactivity in the pigeon retina was investigated by fluorescence immunohistochemistry. NPY-positive cells were found in central and peripheral retina. NPY somata were located in the proximal portion of the inner nuclear layer and their processes directed to the inner plexiform layer where they ramified in 3 immunoreactive bands. NPY might play a role as a neurotransmitter or neuromodulator in the pigeon retina.

Increases in plasma neuropeptide Y concentrations during sympathetic activation in man

Neuropeptide Y (NPY) coexists with noradrenaline in postganglionic sympathetic neurons. In order to test the hypothesis that NPY may be released along with catecholamines by activation of the sympathoadrenal system we measured plasma NPY-like immunoreactivity (NPY-LI) concentrations during cold pressor test, head up tilt and bicycle exercise in healthy volunteers. All 3 manoeuvres resulted in elevation of blood pressure, heart rate and plasma noradrenaline and adrenaline concentrations. These were accompanied by increases in plasma NPY-LI concentrations on cold pressor test and exercise, but not with head up tilt. The increases in both NPY-LI and catecholamines were greatest with exercise. These findings suggest that NPY is released at the same time as noradrenaline when sympathetic noradrenergic nerves are activated.

Effects of periods of conditioning stimulation and of neuropeptides on vagal action at the heart

The strength of action of the parasympathetic innervation of the heart was tested, in anaesthetized dogs, by regular delivery of bursts of supramaximal electrical pulses at low frequency to the cut, cardiac end of the vagus nerve. Periods of 'conditioning' stimulation of the same nerve at relatively high frequencies (15-30 Hz, for 15-300 s) were found to cause a slowly developing potentiation (up to 280% increase in the vagally induced prolongation of pulse interval) of the cardiac action of the low-frequency stimulation. This potentiation lasted for periods of up to 30 min after the conditioning period. Similar potentiation could be elicited for the action of one vagus nerve by conditioning the vagus on the other side. Potentiation of vagal action was not associated with an enhancement of the response of the heart to injected methacholine. Several neuropeptides, reported to be present in cardiac autonomic nerves, were tested for ability to mimic this effect when administered by intravenous injection. Vasoactive intestinal polypeptide, neurotensin, somatostatin and substance P all failed to do so at the doses tested. Vasopressin did induce an enhancement of cardiac vagal efficacy, but effective pharmacological blockade of its action did not block the potentiation caused by conditioning stimulation. In the absence of any evidence of neuromodulation of vagal action by these neuropeptides, it was presumed that the effect could be attributed to a classical homosynaptic post-tetanic potentiation mechanism involving intracellular accumulation of calcium ions in prejunctional nerve terminals.

Peptidergic innervation of human atrial myocardium: an electron microscopical and immunocytochemical study

Nerve terminals of human cardiac muscle were studied using an electron microscope. Substance P-, Leu-enkephalin- and vasoactive intestinal polypeptide-like (VIP) immunoreactive nerves were demonstrated by use of the light microscope. In addition, VIP- and substance P-like immunoreactive nerves were localized ultrastructurally by the peroxidase-antiperoxidase-method. Muscle specimens were obtained from right auricula of patients undergoing open-heart surgery. In the nerve fibres and terminals, which were situated close to the blood vessels and cardiac muscle cells several vesicle populations were identified. On the morphological basis the terminals could be tentatively categorized as cholinergic, mixed cholinergic-peptidergic, adrenergic, sensory or baroreceptor type, peptidergic and degenerating nerve endings. Substance P-, Leu-enkephalin- and VIP-like immunoreactive nerves were localized between cardiac muscle cells. Nerve terminals, which showed substance P-immunoreaction were observed also close to blood vessels. In substance P- and VIP-immunoreactive nerve terminals the immunoprecipitation was localized in large dense-cored vesicles of about 120 nm in diameter. It is concluded that the intrinsic control of the human heart is most probably regulated by several transmitter candidates. The peptidergic nerves may exert their modulatory interactions in the nerve bundles where they are situated close to each other but a direct effect on the blood vessels and muscle cells cannot be excluded.

Culture of intramural cardiac ganglia of the newborn guinea-pig. I. Neuronal elements

The ultrastructure of cultured intrinsic neurones and SIF (small intensely fluorescent) cells dissociated from the atria and interatrial septum of newborn guinea-pig heart has been studied for the first time and compared with these cells in situ. Mononucleate and binucleate neuronal somata and their processes were observed in the culture preparation; their ultrastructure was similar to that of neurones in intracardiac ganglia observed in situ. The number of neurites associated with neuronal cell bodies increased after the first week in culture. A subpopulation of intracardiac neurones showed abnormalities in culture, comparable to the changes previously described in neurones of the monkey heart after unilateral vagotomy in situ. Small granule-containing cells were observed in culture, corresponding to those described in the heart in situ. One type of large process in the culture preparation containing densely packed mitochondria has not been seen in situ, suggesting that changes in cell ultrastructure due to the conditions of culture cannot be discounted. However, the ultrastructure of the cultured cells was, for the most part, consistent with that of the same cell type in situ, indicating that the culture preparation may be a useful model for investigation of the roles and interactions of intramural neurones in the heart, which are inaccessible for such studies in situ.